ERBB2 and neoplasm: One study evaluates the safety of autologous CAR T cells targeting HER2 in subjects with progressive recurrent or refractory HER2‐positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS after standard care interventions (NCT02442297).